126 related articles for article (PubMed ID: 8813139)
21. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 2. The role of non-activated and rIL-2-activated CD4+ and CD8+ T cells in immunotherapy for leukemia.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):153-8. PubMed ID: 10641573
[TBL] [Abstract][Full Text] [Related]
22. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines.
Wang J; Saffold S; Cao X; Krauss J; Chen W
J Immunol; 1998 Nov; 161(10):5516-24. PubMed ID: 9820528
[TBL] [Abstract][Full Text] [Related]
23. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts.
Murphy WJ; Back TC; Conlon KC; Komschlies KL; Ortaldo JR; Sayers TJ; Wiltrout RH; Longo DL
J Clin Invest; 1993 Oct; 92(4):1918-24. PubMed ID: 8408644
[TBL] [Abstract][Full Text] [Related]
24. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.
Cao X; Zhang W; He L; Xie Z; Ma S; Tao Q; Yu Y; Hamada H; Wang J
J Immunol; 1998 Dec; 161(11):6238-44. PubMed ID: 9834111
[TBL] [Abstract][Full Text] [Related]
25. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
Giezeman-Smits KM; Okada H; Brissette-Storkus CS; Villa LA; Attanucci J; Lotze MT; Pollack IF; Bozik ME; Chambers WH
Cancer Res; 2000 May; 60(9):2449-57. PubMed ID: 10811123
[TBL] [Abstract][Full Text] [Related]
26. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
Waller EK; Giver CR; Rosenthal H; Somani J; Langston AA; Lonial S; Roback JD; Li JM; Hossain MS; Redei I
Blood Cells Mol Dis; 2004; 33(3):233-7. PubMed ID: 15528137
[TBL] [Abstract][Full Text] [Related]
27. Effector cells derived from host CD8 memory T cells mediate rapid resistance against minor histocompatibility antigen-mismatched allogeneic marrow grafts without participation of perforin, Fas ligand, and the simultaneous inhibition of 3 tumor necrosis factor family effector pathways.
Zimmerman Z; Shatry A; Deyev V; Podack E; Mammolenti M; Blazar BR; Yagita H; Levy RB
Biol Blood Marrow Transplant; 2005 Aug; 11(8):576-86. PubMed ID: 16041307
[TBL] [Abstract][Full Text] [Related]
28. Bryostatin 1/ionomycin (B/I) ex vivo stimulation preferentially activates L-selectinlow tumor-sensitized lymphocytes.
Chin CS; Miller CH; Graham L; Parviz M; Zacur S; Patel B; Duong A; Bear HD
Int Immunol; 2004 Sep; 16(9):1283-94. PubMed ID: 15262898
[TBL] [Abstract][Full Text] [Related]
29. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti-tumor effects when combined with interleukin-2.
Son YI; Mailliard RB; Watkins SC; Lotze MT
Laryngoscope; 2001 Aug; 111(8):1472-8. PubMed ID: 11568586
[TBL] [Abstract][Full Text] [Related]
30. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
31. Redirected T-cell cytotoxicity to epithelial cell adhesion molecule-overexpressing adenocarcinomas by a novel recombinant antibody, E3Bi, in vitro and in an animal model.
Ren-Heidenreich L; Davol PA; Kouttab NM; Elfenbein GJ; Lum LG
Cancer; 2004 Mar; 100(5):1095-103. PubMed ID: 14983507
[TBL] [Abstract][Full Text] [Related]
32. Superiority of interleukin-12-transduced murine lung cancer cells to GM-CSF or B7-1 (CD80) transfectants for therapeutic antitumor immunity in syngeneic immunocompetent mice.
Sumimoto H; Tani K; Nakazaki Y; Tanabe T; Hibino H; Wu MS; Izawa K; Hamada H; Asano S
Cancer Gene Ther; 1998; 5(1):29-37. PubMed ID: 9476964
[TBL] [Abstract][Full Text] [Related]
33. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW
Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751
[TBL] [Abstract][Full Text] [Related]
34. [Immunobiological characterization of murine LB leukemia and the LBC cell line].
Hajos SE; Mongini C; Waldner C; Sánchez Lockhart M; Gravisaco MJ; Roig I; Fernańdez T; Alvarez E
Medicina (B Aires); 1996; 56 Suppl 1():45-56. PubMed ID: 9224974
[TBL] [Abstract][Full Text] [Related]
35. Effector mechanisms of syngeneic anti-tumour responses in mice. II. Cytotoxic T lymphocytes mediate neutralization and rejection of radiation-induced leukaemia RL male 1 in the nude mouse system.
Keyaki A; Kuribayashi K; Sakaguchi S; Masuda T; Yamashita J; Handa H; Nakayama E
Immunology; 1985 Sep; 56(1):141-51. PubMed ID: 3876272
[TBL] [Abstract][Full Text] [Related]
36. Differential killing of murine B-cell leukemia (BCL1) by photosensitization with merocyanine 540: implications for autologous bone marrow transplantation.
Mumcuoglu M; Weiss L; Spivak J; Slavin S
Bone Marrow Transplant; 1989 Mar; 4(2):143-6. PubMed ID: 2650782
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of cancer gene therapy in aging: adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice.
Provinciali M; Argentati K; Tibaldi A
Gene Ther; 2000 Apr; 7(7):624-32. PubMed ID: 10819579
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and toxicity of 9-beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model.
Gravatt LC; Chaffee S; Hebert ME; Halperin EC; Friedman HS; Kurtzberg J
Leukemia; 1993 Aug; 7(8):1261-7. PubMed ID: 8350627
[TBL] [Abstract][Full Text] [Related]
39. Immune mechanisms in leukemia: evaluation of immunocompetent cell populations.
Lukasewycz OA; Martinez D; Murphy WH
J Immunol; 1975 May; 114(5):1491-6. PubMed ID: 1091703
[TBL] [Abstract][Full Text] [Related]
40. Leukemia cell-rhabdovirus vaccine: personalized immunotherapy for acute lymphoblastic leukemia.
Conrad DP; Tsang J; Maclean M; Diallo JS; Le Boeuf F; Lemay CG; Falls TJ; Parato KA; Bell JC; Atkins HL
Clin Cancer Res; 2013 Jul; 19(14):3832-43. PubMed ID: 23714728
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
